- Sun Pharmaceutical Industries has signed an agreement to acquire the US-based eye care firm InSite Vision.
- InSite Vision now focuses on developing new specialty ophthalmic products. InSite Vision has developed the DuraSite and DuraSite2 drug delivery platforms which are capable of extending the duration of drug retention, which results in lower dosing frequency.
- InSite Vision also has two commercialized products for treatment of bacterial eye infections. It has recently filed a New Drug Application (NDA) with the US FDA for BromSite for treatment of inflammation and prevention of pain associated with cataract surgery.
Sun Pharmaceutical Industries Ltd.
- Headquarters – Mumbai , Maharashtra.
- Founder and CEO – Dilip Shanghvi
No comments:
Post a Comment